https://lyell.com/resource/low-grade-crs-and-icans-with-rondecabtagene-autoleucel/ 2026-06-12T09:00:52+00:00 https://lyell.com/resource/durable-clinical-responses-with-rondecabtagene-autoleucel-dual-targeting-cd19-cd20-car-t-cell-are-associated-with-higher-proportion-of-cytotoxic-t-cells-with-memory-potential-in-infusion-products/ 2026-06-12T09:00:23+00:00 https://lyell.com/resource/lyl314-a-cd19-cd20-car-t-cell-candidate-enriched-for-cd62lstem-like-cells-achieves-high-rates-of-durable-complete-responses-in-r-r-large-b-cell-lymphoma/ 2026-01-08T23:33:38+00:00 https://lyell.com/resource/cd62l-enrichment-achieves-robust-expansion-and-memory-phenotype-post-infusion-in-patients-with-lbcl-treated-with-rondecabtagene-autoleucel-an-autologous-dual-targeting-cd19-cd20-car-t-cell-candidate/ 2026-01-08T23:33:09+00:00 https://lyell.com/resource/rondecabtagene-autoleucel-an-autologous-dual-targeting-cd19-cd20-car-t-cell-candidate-manufactured-from-cd62l-enriched-t-cells-achieves-durable-responses-in-patients-with-large-b-cell-lymphoma/ 2026-01-08T23:32:44+00:00 https://lyell.com/resource/chimeric-antigen-receptor-t-cells-targeting-cd19-and-gcc-in-metastatic-colorectal-cancer-a-nonrandomized-clinical-trial/ 2026-01-08T23:23:02+00:00